Hormone use and lung cancer incidence: The Rancho Bernardo cohort study

Menopause

Volumn 16, Issue 5, 2009, Pages 1044-1048

  Smith, Joshua R ^a   Barrett Connor, Elizabeth ^a   Kritz Silverstein, Donna ^a   Wingard, Deborah L ^a   Al Delaimy, Wael K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormones; Lung cancer; Menopause

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANCHO BERNARDO COHORT ANALYSIS; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; AGED; CALIFORNIA; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG NEOPLASMS; MIDDLE AGED; MORBIDITY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SMOKING;

EID: 73349106198     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a1ba04     Document Type: Article

References (28)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2005.
2. Parkin DM, Sasco AJ. Lung cancer: worldwide variation in occurrence and proportion attributable to tobacco use. Lung Cancer 1993;9:1-16.
3. 3. Brett K.M., Reuben. CA. Prevalence of estrogen or estrogen-progestin hormone therapy use. Obstet Gynecol 2003;102:1240-1249. (Pubitemid 37518402)
4. Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric 2008;11:192-200.
5. 5. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. Maturitas 2001;40:117-130. (Pubitemid 33079171)
6. Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J. Hormone replacement therapy and breast cancer risk in California. Breast J 2005;11:410415.
7. 7. Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral, contraceptives-The Norwegian Women and Cancer study. Int J Cancer 2007;121:645-648. (Pubitemid 46986499)
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. 9. Shah NR, Wong T. Current breast cancer risks of hormone replacement therapy in postmenopausal women. Expert Opin Pharmacother 2006;7:2455-2463. (Pubitemid 44932451)
10. 10. La Vecchia C, Gallus S, Fernandez E. Hormone replacement therapy and colorectal cancer: an update. JBr Menopause Soc 2005;11:166-172. (Pubitemid 43103245)
11. 11. Beral V, Bull D, Reeves G. Endometrial cancer and hormone replacement therapy in the Million Women. Study. Lancet 2005;365:1543-1551. (Pubitemid 40615403)
12. 12. Strom BL, Schinnar R, Weber AL, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006;164:775-786. (Pubitemid 44522082)
13. 13. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833-839. (Pubitemid 20007980)
14. 14. Blackman JA, Coogan PF, Rosenberg L, et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 2002; 11:561-567. (Pubitemid 35345406)
15. Elliott AM, Hannaford PC. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception. Study. Contraception 2006;73:331-335.
16. 16. Kabat GC, Miller AB, Rohan. TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 2007;120:2214-2220. (Pubitemid 46555861)
17. 17. Kreuzer M, Gerken. M, Heinrich J, Kreienbrock. L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003;32:263-271. (Pubitemid 36622273)
18. 18. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 2005;117:662-666. (Pubitemid 41504556)
19. 19. Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 2003;102:565-570. (Pubitemid 37311223)
20. 20. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113-123. (Pubitemid 38114169)
21. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994;86:869-870.
22. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988;48:7279-7284.
23. Rodriguez C, Spencer Feigelson H, Deka A, et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention, study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2008;17:655-660.
24. Fontana RS. Smoking and lung cancer: a review. Bull Schweiz Akad Med Wiss 1979;35:25-31.
25. 25. Archer VE, Coons T, Saccomanno G, Hong DY. Latency and the lung cancer epidemic among United States uranium miners. Health Phys 2004;87:480-489. (Pubitemid 40340621)
26. Finkelstein MM. Use of quot;time windowsquot; to investigate lung cancer latency intervals at an Ontario steel plant. Am J Ind Med 1991;19: 229-235.
27. Hu JF, Liu YY, Yu YK. Estimation of latency period of lung cancer. Zhonghua Zhong Liu Za Zhi 1994;16:18-21.
28. Overview of Menopause and Aging. Available at: http://www. menopause.org/Portals/0/Content/PDF/A.pdf. Accessed March 1, 2007.